TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30925951

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery combined with GnRH agonist (GnRH‐a)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 130
Study: 28188972

Group type: COMPARATOR
Intervention: Supervised exercise with placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Supervised exercise with liraglutide
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Supervised exercise with liraglutide and placebo
Number of subjects: 33
Study: 25788492

Group type: EXPERIMENTAL
Intervention: BNC105P with everolimus (arm A)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Everolimus alone (arm B)
Number of subjects: 139
Study: 23688546

Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Low-dose adjuvanted quadrivalent influenza vaccine (LD QIV-AS)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Trivalent influenza vaccine (TIV)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Low-dose adjuvanted trivalent influenza vaccine (LD TIV-AS)
Number of subjects: 105
Study: 21047278

Group type: EXPERIMENTAL
Intervention: SVH test in healthy subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SVH test in Meniere's patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: oVEMP test in healthy subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: oVEMP test in Meniere's patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: cVEMP test in healthy subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: cVEMP test in Meniere's patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Correlation between SVH and oVEMP tests
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Correlation between SVH and cVEMP tests
Number of subjects: 40
Study: 17904221

Group type: EXPERIMENTAL
Intervention: Cocaine addicts
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cocaine addicts with childhood neglect
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 50
Study: 17931320

Group type: EXPERIMENTAL
Intervention: Group psychosocial intervention (2 hours per week for 2 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Routine unit care and self-care booklet
Number of subjects: 48
Study: 15824913

Group type: EXPERIMENTAL
Intervention: Mivacurium 100 microg kg‐1 followed by pancuronium 15 microg kg‐1 (group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pancuronium 15 microg kg‐1 followed by mivacurium 100 microg kg‐1 (group 2)
Number of subjects: 20
Study: 12234948

Group type: EXPERIMENTAL
Intervention: Intra-arterial vitamin C (24 mg/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vitamin C alone in control experiments
Number of subjects: 8
Study: 9653567

Group type: EXPERIMENTAL
Intervention: Extraperitoneal incision in aorto-iliac occlusive disease
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transperitoneal incision in aorto-iliac occlusive disease
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Retroperitoneal posterolateral approach in aneurysm patients
Number of subjects: 60
Study: 8088389

Group type: EXPERIMENTAL
Intervention: Lumbar epidural anaesthesia (EPI; n = 9) continued for 24 hours postoperatively
Number of subjects: 18

Group type: COMPARATOR
Intervention: General anaesthesia (GA; n = 9) followed by intramuscular analgesics
Number of subjects: 18

Group type: COMPARATOR
Intervention: General anaesthesia (GA; n = 9)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lumbar epidural anaesthesia (EPI; n = 9)
Number of subjects: 18
Study: 2686742

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 30
Study: 31440823

Group type: EXPERIMENTAL
Intervention: Aprepitant plus ondansetron (Arm-A: ondansetron 8 mg days 1-5 with aprepitant day 1: 125 mg, days 2-5: 80 mg)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Ondansetron alone (Arm-B)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Aprepitant plus ondansetron (Arm-A)
Number of subjects: 136
Study: 30905236

Group type: EXPERIMENTAL
Intervention: PUBS
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study: 28420661

Group type: EXPERIMENTAL
Intervention: Structured, person-centred transition programme
Number of subjects: 189

Group type: COMPARATOR
Intervention: Comparison group (standard care)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Intervention-naïve control group
Number of subjects: 189
Study: 25925990

Group type: EXPERIMENTAL
Intervention: Ixabepilone (40mg/m²)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Control (Paclitaxel 175mg/m² or Doxorubicin 60mg/m²)
Number of subjects: 496
Study: 22862847

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazolidinedione
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glargine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21417952

Group type: EXPERIMENTAL
Intervention: Dalteparin (5000 IU once daily)
Number of subjects: 3764

Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU twice daily)
Number of subjects: 3764
Study: 19877975

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Clonidine (CLON)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Combination of MPH and CLON
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 12787857

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 13
Study: 9989682

Group type: EXPERIMENTAL
Intervention: Tocotrienol group (4 capsules daily, each containing 35 mg tocotrienols and 20 mg alpha-tocopherol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo group (4 capsules daily, each providing 20 mg alpha-tocopherol)
Number of subjects: 20
Study: 7578498

Group type: EXPERIMENTAL
Intervention: Icodextrin
Number of subjects: 209

Group type: COMPARATOR
Intervention: Glucose (Control)
Number of subjects: 209
Study: 2183733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 6965333

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Surgical therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Patients who underwent surgery after medical therapy failed
Number of subjects: 96
Study: 31468659

Group type: EXPERIMENTAL
Intervention: Aleglitazar 150 μg
Number of subjects: 7226

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 7226
Study: 31731726

Group type: EXPERIMENTAL
Intervention: 8 weeks biweekly in-season weightlifting training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (standard training program)
Number of subjects: 20
Study: 28726232

Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day for three months
Number of subjects: 28
Study: 26484767

Group type: EXPERIMENTAL
Intervention: Topical Bimatoprost 0.01%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol 0.5% bid
Number of subjects: 0
Study: 23175769

Group type: EXPERIMENTAL
Intervention: HBV vaccination in HIV-1-infected individuals
Number of subjects: 603

Group type: COMPARATOR
Intervention: HBV vaccination in HIV-1-uninfected individuals
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Revaccination with standard HBV vaccine series in HIV-1-infected initial nonresponders
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Overall response including revaccination in HIV-1-infected individuals
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Predictors of nonresponse to initial vaccination in HIV-1-infected individuals
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Predictors of nonresponse to revaccination in HIV-1-infected individuals
Number of subjects: 603
Study: 21293987

Group type: EXPERIMENTAL
Intervention: Triple therapy until cessation of breastfeeding
Number of subjects: 100

Group type: COMPARATOR
Intervention: Short course zidovudine monotherapy
Number of subjects: 100
Study: 19709317

Group type: EXPERIMENTAL
Intervention: Audio-guided decision aid
Number of subjects: 395

Group type: COMPARATOR
Intervention: Booklet decision aid
Number of subjects: 395
Study: 17943989

Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG‐IFN) alpha‐2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for 24 weeks (Group A)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG‐IFN) alpha‐2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for 36 weeks (Group B)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG‐IFN) alpha‐2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for 48 weeks (Group C)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Control group: Pegylated interferon (PEG‐IFN) alpha‐2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for a fixed duration of 48 weeks
Number of subjects: 358
Study: 14764787

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 25 mg/wk
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 50 mg/wk
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 125 mg/wk
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 300 mg/wk
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 600 mg/wk
Number of subjects: 54
Study: 11727452

Group type: EXPERIMENTAL
Intervention: Gavestinel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 10096817

Group type: EXPERIMENTAL
Intervention: Bronchial challenge with HDM extract
Number of subjects: 20

Group type: COMPARATOR
Intervention: Negative skin responders
Number of subjects: 20
Study: 8089246

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine rinse and gum care dentifrice (positive control)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 0.4% chlorhexidine and 0.34% Zn2+ dentifrice (experimental group)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo rinse and gum care dentifrice (control)
Number of subjects: 208
Study: 29453496

Group type: COMPARATOR
Intervention: silorane specific self‐etching adhesive (P90 self‐etch primer and bond) + silorane‐based composite resin (Filtek™ P90 low shrink posterior restorative)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid + silorane specific self‐etching adhesive + silorane‐based composite resin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: blasting with aluminum oxide + silorane specific self‐etching adhesive + silorane‐based composite resin
Number of subjects: 26

Group type: COMPARATOR
Intervention: self‐etching adhesive (Adper™ SE Plus self‐etch adhesive) + dimethacrylate‐based composite resin (Filtek™ P60 posterior restorative)
Number of subjects: 26
Study: 27461663

Group type: EXPERIMENTAL
Intervention: IMRS (Intensity Modulated Radiosurgery)
Number of subjects: 45
Study: 24385182

Group type: EXPERIMENTAL
Intervention: UMEC/VI 125/25 mcg
Number of subjects: 1493

Group type: COMPARATOR
Intervention: UMEC 125 mcg
Number of subjects: 1493

Group type: COMPARATOR
Intervention: VI 25 mcg
Number of subjects: 1493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1493
Study: 23089217

Group type: EXPERIMENTAL
Intervention: Organopathic medicines (OM)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Constitutional medicines (CM)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Combined homeopathic treatment (BCOM)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 220
Study: 20008859

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 159
Study: 19047814

Group type: EXPERIMENTAL
Intervention: Nasal saline irrigation and tapered topical steroid
Number of subjects: 26
Study: 16886935

Group type: EXPERIMENTAL
Intervention: Physiotherapy and craniocervical training programme
Number of subjects: 81

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 81
Study: 15257494

Group type: COMPARATOR
Intervention: Cartilage guide for columella-prosthesis anchoring
Number of subjects: 22
Study: 11761411

Group type: EXPERIMENTAL
Intervention: Dual-chamber ICD (Medtronic 7250 Jewel AF)
Number of subjects: 144
Study: 9403918

Group type: EXPERIMENTAL
Intervention: Client-centered therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Client-centered therapy with additional behavioral exposure treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Client-centered therapy and behavioral exposure treatment
Number of subjects: 40
Study: 8478043

Group type: EXPERIMENTAL
Intervention: Low-dose chlorthalidone
Number of subjects: 0
Study: 2888252

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 42
Study: 29909049

Group type: EXPERIMENTAL
Intervention: Cluster-set (CS) configuration
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Traditional-set (TS) configuration
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 52
Study: 27919865

Group type: EXPERIMENTAL
Intervention: Shared decision making facilitated by a decision aid
Number of subjects: 898

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 898
Study: 24311117

Group type: EXPERIMENTAL
Intervention: Healthy diet intervention including 300g of vegetables and 25ml of plant oil rich in polyunsaturated fatty acids (PUFA) per day for 8 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Information only group (control)
Number of subjects: 97
Study: 23099060

Group type: EXPERIMENTAL
Intervention: L-carnosine (2 g/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 20070756

Group type: EXPERIMENTAL
Intervention: Osstem SSII Implant system
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard Straumann Dental Implant System
Number of subjects: 56
Study: 19216237

Group type: EXPERIMENTAL
Intervention: Qualitative-quantitative design including pre and post phases
Number of subjects: 0
Study: 15657220

Group type: EXPERIMENTAL
Intervention: Early pharmacological stress echocardiography (n = 132)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Conventional pre-discharge maximum symptom limited exercise ECG (n = 130)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Early pharmacological stress echocardiography
Number of subjects: 262

Group type: COMPARATOR
Intervention: Conventional pre-discharge maximum symptom limited exercise ECG
Number of subjects: 262
Study: 12576736

Group type: COMPARATOR
Intervention: Fresh air filtration system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10682201

Group type: EXPERIMENTAL
Intervention: Analogy training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drawing an analogy from two cases
Number of subjects: 0
Study: 9084336

Group type: EXPERIMENTAL
Intervention: Chlorhexidine administration method 1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Chlorhexidine administration method 2
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study: 1831083

Group type: EXPERIMENTAL
Intervention: SCH 34826 400 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SCH 34826 800 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SCH 34826 1600 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7066289

Group type: EXPERIMENTAL
Intervention: High P:S diet (P:S value of 2.0)
Number of subjects: 20
Study: 31982831

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study: 30586691

Group type: EXPERIMENTAL
Intervention: Radiofrequency RDN of the main renal arteries
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Radiofrequency RDN of the main renal arteries, side branches, and accessories
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Endovascular ultrasound-based RDN of the main renal artery
Number of subjects: 120

Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 120
Study: 28138788

Group type: EXPERIMENTAL
Intervention: iBGStar™ + DMApp (experimental meter + telemedicine system)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Traditional glucose meter (Control)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Compliant subjects in iBGStar
Number of subjects: 182

Group type: COMPARATOR
Intervention: Compliant subjects in Control
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Telemedicine users in iBGStar
Number of subjects: 182
Study: 26272719

Group type: EXPERIMENTAL
Intervention: 3 mL of 2% prilocaine (60 mg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: 3 mL of 0.4% plain ropivacaine (12 mg)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study: 24300244

Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 72

Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Endotracheal Intubation (ETI)
Number of subjects: 72
Study: 22951347

Group type: EXPERIMENTAL
Intervention: Electrically Heated Cigarette Smoking System menthol cigarette (EHCSS‐K6(M); 5mg tar and 0.3mg nicotine)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lark One menthol cigarette (Lark1(M); 1mg tar and 0.1mg nicotine)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No smoking
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Serum CC16
Number of subjects: 102
Study: 19205780

Group type: EXPERIMENTAL
Intervention: 10 g of beta-glucan
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Beta-glucan content (0, 2.5, 5, 7.5, and 10 g)
Number of subjects: 17
Study: 17489898

Group type: EXPERIMENTAL
Intervention: Discussion of fecal occult blood test (FOBT) for colorectal cancer screening
Number of subjects: 5978

Group type: EXPERIMENTAL
Intervention: Discussion of mammogram for breast cancer screening (female patients only)
Number of subjects: 5978

Group type: EXPERIMENTAL
Intervention: Discussion of prostate-specific antigen test (PSA) for prostate cancer screening (male patients only)
Number of subjects: 5978
Study: 15590253

Group type: EXPERIMENTAL
Intervention: Nasal fiberoptic intubation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral fiberoptic intubation
Number of subjects: 40
Study: 11755552

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Diabetes on treatment (insulin)
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Diabetes on treatment (oral medications)
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Poor health
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Childbirth
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Vaginal itching
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Vaginal dryness
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Urge incontinence
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Previous urinary tract infections
Number of subjects: 2763
Study: 9203680

Group type: EXPERIMENTAL
Intervention: Antiparasitic therapy
Number of subjects: 48
Study: 7963049

Group type: EXPERIMENTAL
Intervention: Structured medication education
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Unstructured medication education
Number of subjects: 60
Study: 2955117

Group type: EXPERIMENTAL
Intervention: etodolac
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: indomethacin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ibuprofen
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 72

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study: 31912532

Group type: EXPERIMENTAL
Intervention: i-PRF
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MN + i-PRF
Number of subjects: 33
Study: 30987917

Group type: EXPERIMENTAL
Intervention: Agalsidase beta 0.5 mg/kg 2-weekly
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Agalsidase beta 1.0 mg/kg 4-weekly
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 31
Study: 27862727

Group type: EXPERIMENTAL
Intervention: Intradermal injection of type A botulinum toxin (BoNTA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intradermal saline solution injection (Control)
Number of subjects: 40
Study: 25698492

Group type: EXPERIMENTAL
Intervention: AERAS‐402/AD35.TB‐S
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 24581825

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 29

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 29
Study: 22562298

Group type: EXPERIMENTAL
Intervention: Honan intraocular pressure reducer (HIPR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (without HIPR)
Number of subjects: 60
Study: 19120050

Group type: EXPERIMENTAL
Intervention: Video (9.5-minute animated and live-action video)
Number of subjects: 574

Group type: COMPARATOR
Intervention: In-person information session
Number of subjects: 574
Study: 17692742

Group type: EXPERIMENTAL
Intervention: Candesartan and spironolactone (combination group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Candesartan and placebo (control group)
Number of subjects: 51
Study: 15064598

Group type: EXPERIMENTAL
Intervention: Total-body training (TP, N = 18, 3-8 RM training range)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Total-body training (TH, N = 21, 8-12 RM training range)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Upper-body training (UP, N = 21, 3-8 RM training range)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Upper-body training (UH, N = 19, 8-12 RM training range)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (CON, N = 6)
Number of subjects: 85